MetaVia Inc. (NASDAQ:MTVA – Get Free Report) shares passed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $1.49 and traded as high as $1.7756. MetaVia shares last traded at $1.61, with a volume of 463,190 shares.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of MetaVia in a report on Monday, October 19th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $20.00.
Check Out Our Latest Research Report on MetaVia
MetaVia Stock Performance
The stock has a market cap of $8.31 million, a price-to-earnings ratio of -0.50 and a beta of 1.24. The business’s 50 day moving average is $1.49 and its 200 day moving average is $1.64.
MetaVia Company Profile
MetaVia, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. Its work is centered on conditions such as obesity, diabetes and other disorders associated with metabolic dysfunction.
The company’s activities primarily involve the discovery, development and clinical evaluation of potential drug candidates intended to address significant unmet medical needs in metabolic health. As a development-stage biotechnology company, MetaVia’s operations are focused on research programs and advancing therapies through clinical testing rather than on commercialized products.
Publicly available information provides limited detail about MetaVia’s corporate history, geographic operations and leadership.
See Also
- Five stocks we like better than MetaVia
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
